clofibric acid

Summary

Summary: An antilipemic agent and the biologically active metabolite of CLOFIBRATE.

Top Publications

  1. ncbi First-line therapies for lowering triglyceride levels
    Vasudevan A Raghavan
    Am Fam Physician 77:416; author reply 417-8. 2008
  2. ncbi Ultrastructural effects of pharmaceuticals (carbamazepine, clofibric acid, metoprolol, diclofenac) in rainbow trout (Oncorhynchus mykiss) and common carp (Cyprinus carpio)
    R Triebskorn
    Steinbeis Transfer Center for Ecotoxicology and Ecophysiology, Blumenstr 13, 72108 Rottenburg, Germany
    Anal Bioanal Chem 387:1405-16. 2007
  3. ncbi The role of fibric acids in atherosclerosis
    J C Fruchart
    , , 2 Inserm U325, Lille, France
    Curr Atheroscler Rep 3:83-92. 2001
  4. doi The value of repeating studies and multiple controls: replicated 28-day growth studies of rainbow trout exposed to clofibric acid
    Stewart F Owen
    Institute for the Environment, Brunel University, Uxbridge, Middlesex UB8 3PH, United Kingdom
    Environ Toxicol Chem 29:2831-9. 2010
  5. ncbi Acute and chronic effects of clofibrate and clofibric acid on the enzymes acetylcholinesterase, lactate dehydrogenase and catalase of the mosquitofish, Gambusia holbrooki
    B Nunes
    ICBAS, Instituto de Ciencias Biomedicas de Abel Salazar, Departamento de Estudos de Populações, Laboratorio de Ecotoxicologia, Universidade do Porto, Largo Prof Abel Salazar, 2, 4099 003 Porto, Portugal
    Chemosphere 57:1581-9. 2004
  6. pmc Additive effects of clofibric acid and pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet
    Byounghoon Hwang
    Richard Roudebush Veterans Affairs Medical Center, Indianapolis, IN 46202, USA
    FEBS J 279:1883-93. 2012
  7. ncbi Short-term tests with a pilot sewage plant and biofilm reactors for the biological degradation of the pharmaceutical compounds clofibric acid, ibuprofen, and diclofenac
    C Zwiener
    Engler Bunte Institut, Water Chemistry, Universitat Karlsruhe TH, Engler Bunte Ring 1, D 76131 Karlsruhe, Germany
    Sci Total Environ 309:201-11. 2003
  8. ncbi Synthesis and antiplatelet activity of thioaryloxyacids analogues of clofibric acid
    Alessandra Ammazzalorso
    Dipartimento di Scienze del Farmaco, Universita degli Studi G D Annunzio, Via dei Vestini, 66100 Chieti, Italy
    Eur J Med Chem 40:918-21. 2005
  9. ncbi Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac
    Benoît Ferrari
    Laboratoire d éotoxicologie, Cemagref, 3bis quai Chauveau, 69336 Lyon, CP 220, Cedex 09, France
    Ecotoxicol Environ Saf 55:359-70. 2003
  10. doi Oxidation of atenolol, propranolol, carbamazepine and clofibric acid by a biological Fenton-like system mediated by the white-rot fungus Trametes versicolor
    Ernest Marco-Urrea
    Departament d Enginyeria Química and Institut de Ciència i Tecnologia Ambiental, Universitat Autonoma de Barcelona UAB, 08193 Bellaterra, Spain
    Water Res 44:521-32. 2010

Research Grants

  1. CLINICAL STUDIES IN NUTRITION AND METABOLISM
    Ishwarlal Jialal; Fiscal Year: 2007
  2. DIETS FOR DYSLIPIDEMIA IN THE METABOLIC SYNDROME
    Robert Knopp; Fiscal Year: 2007
  3. POSTDOCTORAL TRAINING IN ARTERIOSCLEROSIS RESEARCH
    Henry Ginsberg; Fiscal Year: 2007
  4. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie Ballantyne; Fiscal Year: 2007
  5. C-Reactive Protein And Atherosclerosis
    Ishwarlal Jialal; Fiscal Year: 2007
  6. Clinical and Translational Science Award
    Henry Ginsberg; Fiscal Year: 2007
  7. Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O)
    Lori J Mosca; Fiscal Year: 2010
  8. Role of PPARalpha and L-FABP in Acute Renal Failure
    Didier Portilla; Fiscal Year: 2010
  9. T Cells, Macrophages, Chemokines, and Adiposopathy in Diet-Induced Obesity
    Christie M Ballantyne; Fiscal Year: 2010
  10. DIETS FOR DYSLIPIDEMIA IN THE METABOLIC SYNDROME
    Robert Knopp; Fiscal Year: 2009

Detail Information

Publications189 found, 100 shown here

  1. ncbi First-line therapies for lowering triglyceride levels
    Vasudevan A Raghavan
    Am Fam Physician 77:416; author reply 417-8. 2008
  2. ncbi Ultrastructural effects of pharmaceuticals (carbamazepine, clofibric acid, metoprolol, diclofenac) in rainbow trout (Oncorhynchus mykiss) and common carp (Cyprinus carpio)
    R Triebskorn
    Steinbeis Transfer Center for Ecotoxicology and Ecophysiology, Blumenstr 13, 72108 Rottenburg, Germany
    Anal Bioanal Chem 387:1405-16. 2007
    ..of human pharmaceuticals in aquatic wildlife, laboratory experiments were conducted with carbamazepine, clofibric acid, metoprolol, and diclofenac using fish as test organisms...
  3. ncbi The role of fibric acids in atherosclerosis
    J C Fruchart
    , , 2 Inserm U325, Lille, France
    Curr Atheroscler Rep 3:83-92. 2001
    ..Further clinical studies are necessary to investigate if fibric acids decrease cardiovascular mortality in type 2 diabetes and in primary prevention of hypertriglyceridemia and hypolipidemia...
  4. doi The value of repeating studies and multiple controls: replicated 28-day growth studies of rainbow trout exposed to clofibric acid
    Stewart F Owen
    Institute for the Environment, Brunel University, Uxbridge, Middlesex UB8 3PH, United Kingdom
    Environ Toxicol Chem 29:2831-9. 2010
    Two studies to examine the effect of waterborne clofibric acid (CA) on growth-rate and condition of rainbow trout were conducted using accepted regulatory tests (Organisation for Economic Co-operation and Development [OECD] 215)...
  5. ncbi Acute and chronic effects of clofibrate and clofibric acid on the enzymes acetylcholinesterase, lactate dehydrogenase and catalase of the mosquitofish, Gambusia holbrooki
    B Nunes
    ICBAS, Instituto de Ciencias Biomedicas de Abel Salazar, Departamento de Estudos de Populações, Laboratorio de Ecotoxicologia, Universidade do Porto, Largo Prof Abel Salazar, 2, 4099 003 Porto, Portugal
    Chemosphere 57:1581-9. 2004
    The objective of this study was to investigate both acute and chronic effects of clofibrate and clofibric acid on the enzymes acetylcholinesterase (AChE), lactate dehydrogenase (LDH) and catalase (CAT) of the mosquitofish (Gambusia ..
  6. pmc Additive effects of clofibric acid and pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet
    Byounghoon Hwang
    Richard Roudebush Veterans Affairs Medical Center, Indianapolis, IN 46202, USA
    FEBS J 279:1883-93. 2012
    ..In the present study, the effects of clofibric acid, a PPARα agonist, on blood and liver lipids were determined in wild-type and PDK4 knockout mice fed a high-..
  7. ncbi Short-term tests with a pilot sewage plant and biofilm reactors for the biological degradation of the pharmaceutical compounds clofibric acid, ibuprofen, and diclofenac
    C Zwiener
    Engler Bunte Institut, Water Chemistry, Universitat Karlsruhe TH, Engler Bunte Ring 1, D 76131 Karlsruhe, Germany
    Sci Total Environ 309:201-11. 2003
    The biodegradation of three active compounds of pharmaceuticals clofibric acid, ibuprofen, and diclofenac was investigated in short-term tests with a pilot sewage plant (PSP) and biofilm reactors (BFR, oxic and anoxic) as model systems ..
  8. ncbi Synthesis and antiplatelet activity of thioaryloxyacids analogues of clofibric acid
    Alessandra Ammazzalorso
    Dipartimento di Scienze del Farmaco, Universita degli Studi G D Annunzio, Via dei Vestini, 66100 Chieti, Italy
    Eur J Med Chem 40:918-21. 2005
    The thiophene-, benzothiazole- and pyridine-thioaryloxyacids analogues of clofibric acid were synthesized and their antiplatelet activity was screened. Some compounds exhibited antiaggregating properties...
  9. ncbi Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac
    Benoît Ferrari
    Laboratoire d éotoxicologie, Cemagref, 3bis quai Chauveau, 69336 Lyon, CP 220, Cedex 09, France
    Ecotoxicol Environ Saf 55:359-70. 2003
    ..occurrence in sewage treatment plant (STP) effluents and ecotoxicity of the pharmaceuticals carbamazepine, clofibric acid, and diclofenac were investigated...
  10. doi Oxidation of atenolol, propranolol, carbamazepine and clofibric acid by a biological Fenton-like system mediated by the white-rot fungus Trametes versicolor
    Ernest Marco-Urrea
    Departament d Enginyeria Química and Institut de Ciència i Tecnologia Ambiental, Universitat Autonoma de Barcelona UAB, 08193 Bellaterra, Spain
    Water Res 44:521-32. 2010
    Biological advanced oxidation of the pharmaceuticals clofibric acid (CA), carbamazepine (CBZP), atenolol (ATL) and propranolol (PPL) is reported for the first time...
  11. doi Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor alpha agonists
    Letizia Giampietro
    Dipartimento di Scienze del Farmaco, Universita degli Studi G D Annunzio, Chieti, Italy
    J Med Chem 52:6224-32. 2009
    A series of 2-heteroarylthioalkanoic acids were synthesized through systematic structural modifications of clofibric acid and evaluated for human peroxisome proliferator-activated receptor alpha (PPARalpha) transactivation activity, with ..
  12. ncbi Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein
    James M Backes
    Department of Pharmacy Practice, School of Pharmacy, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160 7231, USA
    Ann Pharmacother 39:523-6. 2005
    ..To review the effects of lipid-lowering therapy on small-dense low-density lipoprotein cholesterol (sdLDL-C)...
  13. ncbi Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials
    Rakesh S Birjmohun
    Department of Vascular Medicine, Academic Medical Center of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Am Coll Cardiol 45:185-97. 2005
    ..The aim of this research was to estimate the efficacy and safety of current high-density lipoprotein cholesterol (HDL-C)-increasing drugs...
  14. ncbi Drugs and personal care products as ubiquitous pollutants: occurrence and distribution of clofibric acid, caffeine and DEET in the North Sea
    Stefan Weigel
    Institute of Organic Chemistry, University of Hamburg, Germany
    Sci Total Environ 295:131-41. 2002
    ..The method was applied to the screening of samples from different North Sea areas for clofibric acid, diclofenac, ibuprofen, ketoprofen, propyphenazone, caffeine and N,N-diethyl-3-toluamide (DEET)...
  15. doi Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9
    Sanae Kourimate
    INSERM U915, CHU Hotel Dieu, 9 quai Moncousu, Nantes, France
    J Biol Chem 283:9666-73. 2008
    ..Moreover, this study validates the functional relevance of a combined therapy associating PCSK9 repressors and statins...
  16. pmc Liver gene expression profiles of rats treated with clofibric acid: comparison of whole liver and laser capture microdissected liver
    Cecile Michel
    Department of Drug Safety Evaluation, Aventis Pharma, Vitry sur Seine, France
    Am J Pathol 163:2191-9. 2003
    b>Clofibric acid (CLO) is a peroxisome proliferator (PP) that acts through the peroxisome proliferator activated receptor alpha, leading to hepatocarcinogenesis in rodents...
  17. ncbi Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-alpha agonist ciprofibrate
    Fekadu Yadetie
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, N 7489 Trondheim, Norway
    Physiol Genomics 15:9-19. 2003
    ....
  18. ncbi Determination of rice herbicides, their transformation products and clofibric acid using on-line solid-phase extraction followed by liquid chromatography with diode array and atmospheric pressure chemical ionization mass spectrometric detection
    T C Santos
    Department of Chemistry, , , Brazil
    J Chromatogr A 879:3-12. 2000
    ..During the 3-month monitoring of the herbicides, 8-hydroxybentazone and 4-chloro-2-methylphenoxyacetic acid were successively found in those samples...
  19. ncbi Pharmacological characterization of chloride channels belonging to the ClC family by the use of chiral clofibric acid derivatives
    M Pusch
    Istituto di Cibernetica e Biofisica, CNR, Genova, Universita di Bari, Bari, Italy
    Mol Pharmacol 58:498-507. 2000
    ..No effects were observed on ClC-5 that shows less than 30% homology with ClC-1. Thus, CPP-like compounds may be useful both to gain insight into biophysical properties of ClC-1 and for searching tissue-specific therapeutic agents...
  20. ncbi Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes
    Lysiane Richert
    Laboratoire de Biologie Cellulaire, UFR SMP, 4, Place Saint Jacques, 25030 Besancon, France
    Toxicol Appl Pharmacol 191:130-46. 2003
    The mRNA expression profile in control and clofibric acid (CLO)-treated mouse, rat, and human hepatocytes was analyzed using species-specific oligonucleotide DNA microarrays (Affymetrix)...
  21. ncbi Clinical practice. Hypertriglyceridemia
    John D Brunzell
    Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, and the Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, USA
    N Engl J Med 357:1009-17. 2007
  22. ncbi Therapeutic roles of peroxisome proliferator-activated receptor agonists
    Bart Staels
    Department of Atherosclerosis, Unité INSERM 545 Institut Pasteur, 1, rue du Professeur Calmette, 59019 Lille Cedex, France
    Diabetes 54:2460-70. 2005
    ..The functions of a third PPAR isoform, PPARdelta, and its potential as a therapeutic target are currently under investigation...
  23. ncbi Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials
    Sander J Robins
    Boston University School of Medicine, Massachussetts, USA
    Curr Opin Lipidol 17:431-9. 2006
    ..This review focuses on a number of extended analyses from these trials that may relate to the success or failure of fibrate therapy and indicate who might likely benefit from this therapy...
  24. ncbi Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883
    P I Eacho
    Toxicology Division, Eli Lilly Company, Greenfield, IN 46140
    Carcinogenesis 12:1557-61. 1991
    ..In these studies, WY-14,643 was compared to clofibric acid, nafenopin and LY171883 given to rats in the diet for up to 30 days...
  25. ncbi Effect of different antilipidemic agents and diets on mortality: a systematic review
    Marco Studer
    Basel Institute for Clinical Epidemiology, University Hospital Basel, CH 4031 Basel, Switzerland
    Arch Intern Med 165:725-30. 2005
    ..Mortality data are the most reliable data to assess efficacy of interventions. We aimed to assess efficacy and safety of different lipid-lowering interventions based on mortality data...
  26. ncbi Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia
    George Liamis
    Department of Internal Medicine, University of Ioannina, Greece
    Curr Med Res Opin 18:125-8. 2002
    ..We conclude that the careful administration of small doses of atorvastatin in patients with mixed dyslipidemia receiving fibrates is associated with a significant amelioration of lipid abnormalities...
  27. ncbi Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
    David J Graham
    Office of of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    JAMA 292:2585-90. 2004
    ..Lipid-lowering agents are widely prescribed in the United States. Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents are not available...
  28. ncbi Comparison of the acute and chronic mitogenic effects of the peroxisome proliferators methylclofenapate and clofibric acid in rat liver
    N C Barrass
    Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK
    Carcinogenesis 14:1451-6. 1993
    ..of acute (1 week) and chronic (26 week) exposure to the peroxisome proliferators methylclofenapate (MCP) and clofibric acid (CA), at 0.05 and 0.5% in the diet respectively, on hepatocyte replication in the Sprague-Dawley rat...
  29. pmc Properties of Ca(2+) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres
    T Ikemoto
    Department of Pharmacology, Saitama Medical School, Moroyama machi, Saitama 350 0495, Japan
    Br J Pharmacol 134:719-28. 2001
    1. To characterize the effect of clofibric acid (Clof) on the Ca(2+) release mechanism in the sarcoplasmic reticulum (SR) of skeletal muscle, we analysed the properties of Clof-induced Ca(2+) release under various conditions using ..
  30. ncbi Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer
    Yoshihito Yokoyama
    Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Amori, Japan
    Mol Cancer Ther 6:1379-86. 2007
    ..In this study, we investigated the inhibitory effect of clofibric acid (CA), a ligand for PPARalpha on growth of ovarian malignancy, in in vivo and in vitro experiments using OVCAR-..
  31. ncbi Differential induction of peroxisomal beta-oxidation enzymes by clofibric acid and aspirin in piglet tissues
    X X Yu
    Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
    Am J Physiol Regul Integr Comp Physiol 281:R1553-61. 2001
    ..5% clofibric acid (CA) or 1% aspirin for 14 days. CA increased ratios of liver weight to body weight (P < 0...
  32. ncbi Hepatic beta-oxidation and carnitine palmitoyltransferase I in neonatal pigs after dietary treatments of clofibric acid, isoproterenol, and medium-chain triglycerides
    Pasha Lyvers Peffer
    Department of Animal Science, North Carolina State University, Raleigh, NC, USA
    Am J Physiol Regul Integr Comp Physiol 288:R1518-24. 2005
    ..The long-chain control diet was supplemented further with clofibric acid (0.5%) or isoproterenol (40 ppm), and growth was monitored for 10-12 days...
  33. ncbi Effects of the peroxisome proliferator clofibric acid on superoxide dismutase expression in the human HepG2 hepatoma cell line
    P Becuwe
    Laboratoire de Biologie Cellulaire du Developpement, Upres 2402 Proliferateurs de Peroxysomes, Universite Henri Poincare Nancy I, Faculte des Sciences, Vandoeuvre les Nancy, France
    Biochem Pharmacol 58:1025-33. 1999
    We examined the effects of clofibric acid, a peroxisome proliferator, on the production of superoxide radicals, on the levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), and on the expression of superoxide dismutases (SODs) in ..
  34. ncbi Clofibric acid stimulates branched-chain amino acid catabolism by three mechanisms
    Rumi Kobayashi
    Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202 5122, USA
    Arch Biochem Biophys 407:231-40. 2002
    ..WY-14,643, which, like clofibric acid, is a ligand for the peroxisome-proliferator-activated receptor alpha [PPARalpha], does not directly inhibit ..
  35. ncbi Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
    Sander J Robins
    Division of Endocrinology, Nutrition, and Diabetes, Boston University School of Medicine, Evans 201, 88 East Newton Street, Boston, MA 02118, USA
    Curr Opin Lipidol 14:575-83. 2003
    ....
  36. ncbi Role for fibrate therapy in diabetes: evidence before FIELD
    Bruno Verges
    Service Endocrinologie, diabétologie et maladies métaboliques, Centre Hospitalier, Universitaire de Dijon, and INSERM U498, Faculte de Medecine, Dijon, France
    Curr Opin Lipidol 16:648-51. 2005
    ..Statins have been shown to diminish significantly the risk for coronary disease in patients with type 2 diabetes, and so what are the real effects of fibrates on cardiovascular risk in type 2 diabetes?..
  37. ncbi Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemia
    I Bakke
    Department of Physiology and Biomedical Engineering, Norwegian University of Science and Technology, Trondheim, Norway
    J Mol Endocrinol 25:109-19. 2000
    ..Ciprofibrate stimulates gastrin cell activity by a mechanism unaffected by octreotide, but octreotide does inhibit basal and gastrin-stimulated ECL cell function and growth...
  38. ncbi Role of fibric acid derivatives in the management of risk factors for coronary heart disease
    Jean Pierre Despres
    Quebec Heart Institute, Laval Hospital Research Center, Quebec, Canada
    Drugs 64:2177-98. 2004
    ....
  39. pmc Management of dyslipidemia in women in the post-hormone therapy era
    Lori Mosca
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    J Gen Intern Med 20:297-305. 2005
    ..This article reviews these recommendations and the evidence supporting them...
  40. ncbi Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
    S Tavintharan
    Department of Medicine, Alexandra Hospital, 378 Alexandra Road, Singapore 159964
    Singapore Med J 46:519-28. 2005
    ..CETP inhibitors show greater HDL-C rising, but are still used in trial settings only. HDL mimetic agents are another group of agents that offer much promise. Clinical outcome data are awaited for these newer therapeutic agents...
  41. ncbi Management of diabetic dyslipidemia: need for reappraisal of the goals
    Amit Khera
    Division of Cardiology and the Donald W Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9047, USA
    Am J Cardiovasc Drugs 5:83-91. 2005
    ..Several ongoing trials of various pharmacologic agents should help clarify the role of these agents alone and in combination with HMG-CoA reductase inhibitors in the management of diabetic dyslipidemia...
  42. ncbi Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention
    M John Chapman
    Institut National de la Santé et de la Recherche Mé dicale, Hopital de la Pitie, Paris, France
    Cardiovasc Drugs Ther 19:135-9. 2005
    ..Given that the prevalence of low HDL-C, particularly amongst individuals with CHD, is higher than previously anticipated, combining nicotinic acid and a statin represents an innovative approach to further reducing CHD risk...
  43. ncbi Assessment of compliance with lipid guidelines in an academic medical center
    Sarah J Schwiesow
    Kaiser Permanente, Highlands Ranch, CO 80129 2262, USA
    Ann Pharmacother 40:27-31. 2006
    ..Emerging evidence supports the recognition and management of secondary lipid goals, high-density lipoprotein cholesterol (HDL-C) level greater than 40 mg/dL, and triglyceride level less than 150 mg/dL...
  44. ncbi Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions
    Michael H Davidson
    Rush University, Preventive Cardiology Center, Rush Presbyterian St Luke s Medical Center, 515 State Street, Suite 2700, Chicago, IL, USA
    Expert Opin Drug Saf 5:145-56. 2006
    ..The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study in 10,000 patients with Type 2 diabetes mellitus is testing the efficacy and safety of fenofibrate/statin combination...
  45. ncbi Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates
    Bogusław Okopień
    Department of Clinical Pharmacology, Medical University of Silesia, Medykow 18, PL 40 752 Katowice, Poland
    J Cardiovasc Pharmacol 46:377-86. 2005
    ..The statin- and fibrate-induced suppression of proinflammatory cytokine release from monocytes seems to play a role in their beneficial effect on the incidence of cardiovascular events...
  46. ncbi [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care]
    Zoltán Jancsó
    Debreceni Egyetem, Orvos és Egészségtudományi Centrum, Általános Orvostudományi Kar, Családorvosi Tanszék
    Orv Hetil 146:2629-33. 2005
    ..The role of dyslipidemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidemic patients is an extremely important task in cardiovascular prevention...
  47. ncbi Lipids in type 2 diabetes
    Markku Laakso
    Department of Medicine, University of Kuopio, Kuopio, Finland
    Semin Vasc Med 2:59-66. 2002
    ....
  48. ncbi Low-density lipoprotein size and cardiovascular risk assessment
    M Rizzo
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy
    QJM 99:1-14. 2006
    ....
  49. ncbi Differential associations of statin and fibrate treatment with carotid arterial remodeling
    Gilles Chironi
    Centre de Medecine Preventive Cardiovasculaire, Hôpital Broussais Assistance Publique Hôpitaux de Paris and Faculté de Médecine Paris 5, Paris, France
    Am J Hypertens 18:1476-81. 2005
    ..The effects of statins on intima-media thickness (IMT) are well documented, whereas those of fibrates are unknown. Therefore we compared IMT under treatment with each class of drugs...
  50. ncbi Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    John J P Kastelein
    Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Am J Cardiol 96:20K-27K; discussion 34K-35K. 2005
    ..Management of the metabolic syndrome focusing on the modification of plasma LDL as well as high-density lipoprotein cholesterol is reviewed. Future management strategies with the use of novel combination therapy is also discussed...
  51. ncbi Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events
    Ebrahim A Balbisi
    Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St John s University, New York, NY, USA
    Med Sci Monit 12:RA34-9. 2006
    ..In spite of the challenges, there are ample opportunities for improving the management of hyperlipidemia. Adherence to the recommendations will vastly reduce morbidity and mortality associated with CHD...
  52. ncbi Strategies for management and treatment of dyslipidemia in HIV/AIDS
    P E Sax
    Division of Infection, Diseases and HIV Program, Brigham and Women s Hospital, Boston, MA 02115, USA
    AIDS Care 18:149-57. 2006
    ..Each approach is associated with advantages and limitations and the need to maintain viral suppression must be balanced with the need to treat abnormal lipid levels...
  53. ncbi Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism
    Jean Charles Fruchart
    Lipoprotein and Atherosclerosis Research Unit, INSERM Unité de Recherche sur l Arthérosclérose and Lille University 2 U545, Pasteur Institute of Lille, Lille, France
    Drugs Today (Barc) 42:39-64. 2006
    ..PPARs are also expressed in atherosclerotic lesions...
  54. ncbi Is there evidence for the evidence-based guidelines for cardiovascular disease prevention in women?
    Barbara H Roberts
    The Women s Cardiac Center at The Miriam Hospital, Providence, RI 02906, USA
    Gend Med 3:5-12. 2006
  55. ncbi Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cornerstone 8:S6-13. 2007
    ..Weight loss has also been shown to improve risk factors associated with metabolic syndrome...
  56. ncbi The treatment of dyslipidemia--what's left in the pipeline?
    Oliver Rau
    Institute of Pharmaceutcial Chemistry ZAFES, Johann Wolfgang Goethe University Frankfurt, Max von Laue Strasse 9, 60438 Frankfurt, Germany
    ChemMedChem 3:206-21. 2008
    ..Clinical implications of new drugs under investigation are discussed in this review...
  57. ncbi Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease
    Michael H Davidson
    Pritzker School of Medicine, University of Chicago, Chicago, IL, USA
    Am Heart Hosp J 5:210-6. 2007
    ..This article reviews the strategies for targeting HDL cholesterol to optimize outcomes in CHD...
  58. pmc Management of hyperlipidemia with statins in the older patient
    Wilbert S Aronow
    Department of Medicine, Cardiology and Geriatrics Divisions, New York Medical College, Valhalla, NY 10595, USA
    Clin Interv Aging 1:433-8. 2006
    ..When LDL cholesterol-lowering drug therapy is used to treat high-risk persons or moderately high-risk persons, the serum LDL cholesterol should be decreased at least 30% to 40%...
  59. ncbi High-density lipoprotein metabolism: potential therapeutic targets
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 100:n32-40. 2007
    ....
  60. ncbi [Adverse effects of lipid-lowering medications]
    Yoshihiro Fukumoto
    Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine
    Nihon Rinsho 65:165-72. 2007
  61. doi Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents
    A M Dupuy
    INSERM U888, Montpellier, France
    Climacteric 11:74-83. 2008
    ..To evaluate plasma lipid levels in elderly women in the general population as a function of use of lipid-lowering agents (LLA) and hormone therapy (HT)...
  62. ncbi [Therapy of dyslipidemia in post-infarction: state of the art]
    M C Borgia
    Dipartimento di Scienze Cliniche, Universita Sapienza, Roma, Italia
    Clin Ter 158:523-32. 2007
    ..The innovative therapeutic approach to hypercholesterolemia today is based on a double inhibition of cholesterol synthesis and absorption combining a statin with ezetimibe...
  63. ncbi Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
    Eliot A Brinton
    Cardiovascular Genetics, University of Utah School of Medicine, 420 Chipeta Way, Room 1160, Salt Lake City, UT 84108, USA
    Curr Atheroscler Rep 10:25-32. 2008
    ..This review provides an update on the benefits and risks of fibrate monotherapy and addresses the benefits and risks of adding fibrates to statins...
  64. doi Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes
    Madiha Abdel-Maksoud
    Department of Public Health, Preventive, and Social Medicine, Tanta University, Egypt
    J Cardiovasc Pharmacol 51:331-51. 2008
    ....
  65. ncbi Hypertriglyceridemia and cardiovascular disease management
    Ronald A Codario
    J Am Acad Nurse Pract 19:7-10, 13-4. 2007
  66. doi Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
    Bart Staels
    Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France
    Nat Clin Pract Cardiovasc Med 5:542-53. 2008
    ....
  67. ncbi [When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis]
    M Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon
    Arch Mal Coeur Vaiss 100:569-81. 2007
  68. pmc Treating hypertriglyceridemia
    Bruce J Holub
    CMAJ 177:604; author reply 604-5. 2007
  69. pmc Treating hypertriglyceridemia
    Georg Roggla
    CMAJ 177:603; author reply 604-5. 2007
  70. ncbi [Treatment of dyslipidemia: how and when to combine lipid lowering drugs]
    Isio Schulz
    Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP
    Arq Bras Endocrinol Metabol 50:344-59. 2006
    ..Niacin causes flushing, that can in part be managed with use of aspirin and extended release forms (Niaspan); niacin also may increase plasma glucose and uric acid levels. Evaluation of risks and benefits for each patient is needed...
  71. ncbi Dyslipidaemia, hypercoagulability and the metabolic syndrome
    Anna I Kakafika
    Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, London, UK
    Curr Vasc Pharmacol 4:175-83. 2006
    ..Obesity and sedentary lifestyle coupled with genetic factors interact to produce the syndrome. Here, we consider two components of the metabolic syndrome, dyslipidaemia and hypercoagulability...
  72. ncbi [Clinical trials of statins and fibrates --a meta-analysis]
    Vid Stanulović
    Accelsiors CRO and Consultancy Services, Budapest, Hungary
    Med Pregl 59:213-8. 2006
    ..The question remains: which trial should be the basis of clinical decision making in the choice of hypolipidemic therapy?..
  73. ncbi [Favorable effects of decreasing lipids in patients with diabetes mellitus]
    I Gouni-Berthold
    Klinik II und Poliklinik für Innere Medizin der Universität zu Köln, Koln, Germany
    Dtsch Med Wochenschr 131:S252-4. 2006
    ..Therefore, at present no specific recommendation for treatment of diabetics with fibrates can be made...
  74. ncbi Fibrates after the FIELD study: Some answers, more questions
    Anthony S Wierzbicki
    St Thomas Hospital, London, SE1 7EH, UK
    Diab Vasc Dis Res 3:166-71. 2006
    ....
  75. ncbi [New indications and therapeutic objectives for dyslipidemia]
    Antonio Maiques Galán
    Aten Primaria 38:473-5. 2006
  76. ncbi Fibrates: what have we learned in the past 40 years?
    James M Backes
    Department of Pharmacy Practice, University of Kansas School of Pharmacy, Lawrence, Kansas, USA
    Pharmacotherapy 27:412-24. 2007
    ..Nearly 40 years after the introduction of the fibrates, practitioners are still contemplating the role of these agents in the treatment of CHD...
  77. ncbi Expert commentary: the safety of fibrates in lipid-lowering therapy
    W Virgil Brown
    Emory University School of Medicine, Atlanta, Georgia, USA
    Am J Cardiol 99:19C-21C. 2007
    ..To date, there has been no study exclusive to patients with elevated triglycerides, raising the question of the potential benefit of these drugs in patients with the lipid abnormalities most effectively treated with fibrates...
  78. pmc Hypertriglyceridemia: its etiology, effects and treatment
    George Yuan
    Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ont
    CMAJ 176:1113-20. 2007
    ..We review the causes and classification of elevated triglyceride levels, the clinical manifestations of primary hypertriglyceridemia and the management of patients with elevated triglyceride levels...
  79. ncbi [Metabolically designed treatments: from biochemistry to the vessel lining]
    P Moulin
    Fédération d endocrinologie diabétologie maladies métaboliques nutrition, Hopital Cardiovasculaire Louis Pradel, 69677 Bron, France
    Rev Med Interne 28:S12-3. 2007
  80. ncbi Management of hypertriglyceridemia
    Robert C Oh
    Family Medicine Residency Program, Tripler Army Medical Center, Honolulu, Hawaii 96859, USA
    Am Fam Physician 75:1365-71. 2007
    ..e., 500 mg per dL [5.65 mmol per L] or higher) is aimed at reducing the risk of acute pancreatitis. Statins, fibrates, niacin, and fish oil (alone or in various combinations) are effective when pharmacotherapy is indicated...
  81. ncbi Hypertriglyceridemia and cardiovascular risk reduction
    Terry A Jacobson
    Office of Health Promotion and Disease Prevention, Emory University, Atlanta, GA 30303, USA
    Clin Ther 29:763-77. 2007
    ..There is evidence that elevated TG levels may be a significant independent risk factor for coronary heart disease (CHD), particularly in women...
  82. pmc Treating hypertriglyceridemia
    Irfan Yavasoglu
    CMAJ 177:603-4; author reply 604-5. 2007
  83. ncbi Is it time to stop treating dyslipidaemia with fibrates?
    Jocelyne R Benatar
    Cardiovascular Research Unit, Green Lane Clinical Centre, Green Lane, Auckland
    N Z Med J 120:U2706. 2007
    ..To determine whether evidence from randomised clinical trials supports the use of fibrates to reduce non-fatal and fatal cardiovascular events in patients with dyslipidaemia...
  84. ncbi Rationale for combination therapy with statin drugs in the treatment of dyslipidemia
    Benjamin J Ansell
    Division of General Internal Medicine Cardiology, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA
    Curr Atheroscler Rep 7:29-33. 2005
    ..More recently, however, it has been recognized that the potential complications of this combination are far outweighed by the clinical benefits that are possible...
  85. ncbi [Nuclear receptors PPARalpha]
    V Soska
    Centrum pro diagnostiku a lécbu dyslipidemií Oddelení klinického komplementu FN u sv Anny, Brno
    Vnitr Lek 52:628-31. 2006
    ..These effects are very important in patients with metabolic syndrom...
  86. ncbi Utility of currently available modes of therapy in reaching lipid goals
    Kelly Anne Spratt
    University of Pennsylvania Health System, Cardiovascular Division, Philadelphia Heart Institute, Second Floor, 39th and Market Streets, Philadelphia, PA 19104, USA
    J Am Osteopath Assoc 104:S14-6. 2004
    ..In addition, nonprescription agents such as plant stanols and sterols are available to modify plasma lipid levels. These agents can be used individually or coadministered to achieve lipid goals...
  87. ncbi Coadministration of multidrug therapy to achieve lipid goals
    Margo A Denke
    The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284, USA
    J Am Osteopath Assoc 104:S17-22. 2004
    ..The coadministration of low doses of these agents has been proved to be as effective as high-dose statin therapy in reducing LDL-C levels and assisting patients achieve their treatment goals...
  88. ncbi [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates]
    M Zeman
    IV interni klinika 1 LF UK a VFN, Praha
    Cas Lek Cesk 142:500-4. 2003
    ..Aim of the study was to evaluate efficacy and safety of long-term treatment of pravastatin + fenofibrate or simvastatin + ciprofibrate therapy in the high-risk group of patients with severe mixed hyperlipoproteinemia...
  89. doi Managing dyslipidemia in chronic kidney disease
    Charles R Harper
    Department of Medicine, Emory University, Atlanta, Georgia 30303, USA
    J Am Coll Cardiol 51:2375-84. 2008
    ..After reviewing the safety and dose alterations required in managing dyslipidemia in patients with CKD, a practical treatment algorithm is proposed...
  90. ncbi Current drug treatments for lipid management
    Neil J Stone
    Feinberg School of Medicine, Northwestern University, Chicago, USA
    Manag Care 11:4-9. 2002
  91. ncbi [Low HDL-cholesterol, high triglycerides--well known but often ignored]
    R Benz
    Medizinische Poliklinik, Hypertonie und Adipositassprechstunde, Universitatsspital Zurich
    Praxis (Bern 1994) 93:1911-6. 2004
    ..We therefore want to show the relation of the triglyzerides with the HDL-Cholesterol and the nonpharmacologic treatment of these two factors. Some clinical examples are illustrating the topic...
  92. ncbi Treatment of dyslipoproteinemia in the metabolic syndrome
    A Steinmetz
    St. Nikolaus-Stiftshospital, Teaching Hospital, University of Bonn at Andernach, Germany
    Exp Clin Endocrinol Diabetes 109:S548-59. 2001
    ..However studies still are needed showing definite evidence on differential therapy in lipid lowering based on prospective controlled trials with endpoints of macro- and microangiopathy in diabetic patients...
  93. ncbi Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia
    Vasilios G Athyros
    Lipid Out patient Clinic, Division of Cardiology, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki, 546 42, Greece
    J Cardiovasc Risk 9:33-9. 2002
    ..Nonetheless, they have not been extensively used because of the fear of side effects. Thus, a therapeutic alternative is required for this lipid disorder...
  94. ncbi Role of hepatic fatty acid:coenzyme A ligases in the metabolism of xenobiotic carboxylic acids
    K M Knights
    Department of Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Flinders University of South Australia, Australia
    Clin Exp Pharmacol Physiol 25:776-82. 1998
    ..g. clofibric acid) and of the R(-)-enantiomers of the commonly used 2-arylpropionic acid non-steroidal anti-inflammatory drugs (..
  95. ncbi Expression of rabbit cytochromes P4504A which catalyze the omega-hydroxylation of arachidonic acid, fatty acids, and prostaglandins
    L J Roman
    Department of Biochemistry, University of Texas Health Science Center at San Antonio 78284 7760
    Arch Biochem Biophys 307:57-65. 1993
    ..is the most abundant of the mRNAs, but it was not induced in kidney and only moderately (2-fold) in liver by clofibric acid. CYP4A7 exhibits a similar pattern of induction by clofibrate...
  96. ncbi The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing
    T Nishimaki-Mogami
    National Institute of Health Sciences, Tokyo, Japan
    Biochim Biophys Acta 1304:21-31. 1996
    ..We have shown that bezafibrate and clofibric acid, known hypolipidemic agents, are potent inhibitors of PE methylation (see accompanying paper by Nishimaki-..
  97. doi Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms
    Roberto Rosal
    Departamento de Ingenieria Quimica, Universidad de Alcala, 28871 Alcala de Henares, Madrid, Spain
    Environ Sci Pollut Res Int 17:135-44. 2010
    ..This paper describes a study undertaken to evaluate the acute toxicity of bezafibrate, clofibric acid, gemfibrozil, and fenofibric acid, a metabolite of fenofibrate whose ecotoxicity has not been previously ..
  98. ncbi Pharmaceutical and personal care products in sewage treatment works
    Rakesh Kanda
    WRc NSF Limited, Henley Road, Medmenham, Marlow, Buckinghamshire, UK SL7 2HD
    J Environ Monit 5:823-30. 2003
    ..this study a number of PPCPs including painkillers (aspirin, ibuprofen), cholesterol control medication (clofibric acid), antibacterial agents (triclosan), musks (including galaxolide and tonalide), X-ray contrast media (..
  99. ncbi Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada
    Chris D Metcalfe
    Water Quality Centre, Trent University, Peterborough, Ontario K9J 7B8, Canada
    Environ Toxicol Chem 22:2881-9. 2003
    ..However, clofibric acid, ketoprofen, fenoprofen, and carbamazepine were detected in samples collected in the summer of 2000 at sites ..
  100. pmc Induction of acyl-CoA oxidase and cytochrome P450IVA1 RNA in rat primary hepatocyte culture by peroxisome proliferators
    D R Bell
    Biochemical Toxicology, ICI Central Toxicology Laboratory, Macclesfield, Cheshire, U K
    Biochem J 280:249-53. 1991
    ..Hepatocytes were cultured with a maximal inducing dose of the peroxisome proliferator clofibric acid (1 mM), or vehicle control, for 4 days, and the level of RNAs compared with the level in rats which had been ..
  101. ncbi Bioactivation of carboxylic acid compounds by UDP-Glucuronosyltransferases to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicity
    Benedetta C Sallustio
    Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville 5011, Australia
    Chem Res Toxicol 19:683-91. 2006
    ..We have previously reported that clofibric acid undergoes glucuronidation-dependent bioactivation to DNA-damaging species in cultured mouse hepatocytes...

Research Grants93

  1. CLINICAL STUDIES IN NUTRITION AND METABOLISM
    Ishwarlal Jialal; Fiscal Year: 2007
    ....
  2. DIETS FOR DYSLIPIDEMIA IN THE METABOLIC SYNDROME
    Robert Knopp; Fiscal Year: 2007
    ..This study will be the first to demonstrate dietary benefit for dyslipidemia, inflammation and vascular stress in MetS at stable weight. ..
  3. POSTDOCTORAL TRAINING IN ARTERIOSCLEROSIS RESEARCH
    Henry Ginsberg; Fiscal Year: 2007
    ..D. and Ph.D. faculty, other M.D. and Ph.D. postdoctoral scientists, and graduate students. A pro-active program to enhance recruitment of scientists from underrepresented ethnic groups is proposed. ..
  4. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie Ballantyne; Fiscal Year: 2007
    ....
  5. C-Reactive Protein And Atherosclerosis
    Ishwarlal Jialal; Fiscal Year: 2007
    ..Thus, these studies will clearly provide us with further scientific evidence in support of the role of CRP in atherothrombosis. ..
  6. Clinical and Translational Science Award
    Henry Ginsberg; Fiscal Year: 2007
    ..Pediatfic and community-based G/T research will receive special attention. The IICTR and CTSA will break down the barriers impeding movement of new knowledge from the bench to the bedside and community. ..
  7. Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O)
    Lori J Mosca; Fiscal Year: 2010
    ..Improved adherence to evidence-based preventive therapies could have a substantial public health benefit. ..
  8. Role of PPARalpha and L-FABP in Acute Renal Failure
    Didier Portilla; Fiscal Year: 2010
    ....
  9. T Cells, Macrophages, Chemokines, and Adiposopathy in Diet-Induced Obesity
    Christie M Ballantyne; Fiscal Year: 2010
    ..To test our hypothesis, we will study the effects of diet-induced obesity on a number of factors related to inflammation in mice and also in human fat cells. ..
  10. DIETS FOR DYSLIPIDEMIA IN THE METABOLIC SYNDROME
    Robert Knopp; Fiscal Year: 2009
    ..This study will be the first to demonstrate dietary benefit for dyslipidemia, inflammation and vascular stress in MetS at stable weight. ..
  11. CRP, Diabetes, Atherothrombosis
    Ishwarlal Jialal; Fiscal Year: 2010
    ..CRP augments oxidative stress and inflammation in the diabetic milieu will eventually lead to therapies targeted at reducing inflammation and oxidative stress in diabetes and resulting in a decrease in vasculopathies ..
  12. NUTRITION ACADEMIC AWARD
    Robert Knopp; Fiscal Year: 2002
    ..It is time to begin aggressive, substantive nutrition educational programs in cardiovascular disease prevention. ..
  13. REGULATION OF HEPATIC P450S BY ANTICHOLESTEROL DRUGS
    THOMAS KOCAREK; Fiscal Year: 2003
    ..These studies will provide information with practical implications for the development of improved anti-cholesterol drugs, and will illuminate mechanisms whereby a cell recognizes, responds to, and metabolizes foreign chemicals. ..
  14. MOLECULAR & CLINICAL EVALUATION OF LOW HDL SYNDROMES
    Michael Miller; Fiscal Year: 2003
    ..Further understanding of the molecular basis of isolated low HDL-C and its potential clinical sequelae (e.g., CAD), may therefore aid in the development of therapeutic strategies to effectively treat this disorder. ..
  15. EFFECT OF HIGH DOSE VITAMIN E ON CAROTID ATHERSCLEROSIS
    Ishwarlal Jialal; Fiscal Year: 2001
    ..If this study show that high-dose AT supplementation is beneficial in retarding atherosclerosis this could emerge as an important adjunctive therapy in the management of cardiovascular disease. ..
  16. NUTRITION ACADEMIC AWARD
    Michael Miller; Fiscal Year: 2004
    ..Compliance with ATP II and JNC VI recommendations will also be assessed. In addition, medical students' diets and blood lipid levels will be assessed and tracked. ..
  17. Regulation of Hepatic P450s by Anti-Cholesterol Drugs
    THOMAS KOCAREK; Fiscal Year: 2007
    ..These studies will provide essential new information about the pharmacology of a widely-used class of drugs, and important insights into the mechanisms underlying inducible P450 expression. ..
  18. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie Ballantyne; Fiscal Year: 2009
    ....
  19. ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN
    John Gerich; Fiscal Year: 2002
    ..Better understanding of the pathogenesis of hypoglycemia unawareness and abnormal glucose counterregulation should make treatment of diabetes safer and improve the chances of achieving optimal glycemic control. ..
  20. Role of PPARalpha and L-FABP in Acute Renal Failure
    Didier Portilla; Fiscal Year: 2007
    ....
  21. HDL and Vascular Injury in Type 2 Diabetes
    C White; Fiscal Year: 2007
    ....
  22. AIM HIGH: Niacin Plus Statin to Prevent Vascular Events
    Bruce Brown; Fiscal Year: 2007
    ..In summary, statins have little effect on HDL-C orTG, and only moderately reduce CV risk. AIM-HIGH is designed to confirm a substantially greater benefit from "complete" lipid therapy using statins plus niacin. ..
  23. Myeloperoxidase and NO signaling in the vasculature
    C White; Fiscal Year: 2004
    ..The HOCI-dependent modification of L-arginine may represent a common pathogenic mechanism underlying endothelial dysfunction in diverse cardiovascular diseases. ..
  24. Applied Preventive Cardiology Research
    Lori Mosca; Fiscal Year: 2007
    ..The research and careers supported by this project are expected to have a positive impact on attainment of the Healthy People 2010 lifestyle and CVD prevention. ..
  25. ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MAN
    John Gerich; Fiscal Year: 2007
    ..Further knowledge of the control of renal glucose release could therefore have therapeutic implications for this disorder and in people with liver and kidney disease. ..
  26. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  27. The Effect of Statins on Skeletal Muscle Function
    Paul Thompson; Fiscal Year: 2009
    ....
  28. PROTEASE INHIBITOR-INDUCED HYPERLIPIDEMIA IN AIDS
    Virgil Brown; Fiscal Year: 2004
    ..These are specific agents that are effective in reducing triglyceride as well as improving insulin resistance. ..
  29. Effectiveness of a Family Heart Health Intervention
    Lori Mosca; Fiscal Year: 2007
    ..This study will provide important information about the effectiveness of a novel program to identify persons at risk of CHD and increase attainment of Healthy People 2010 Objectives. ..
  30. The Effect of Statins on Skeletal Muscle Function
    Paul Thompson; Fiscal Year: 2007
    ....